U.S. markets closed

Dicerna Pharmaceuticals, Inc. (DRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.30+0.27 (+1.28%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close21.03
Bid21.29 x 1100
Ask21.31 x 4000
Day's Range20.82 - 22.04
52 Week Range17.76 - 40.14
Avg. Volume1,042,475
Market Cap1.656B
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dicerna Pharmaceuticals, Inc.
    ARWR: Lowering target price to $65.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $65.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    Dicerna Announces New Executive Leadership Appointments

    LEXINGTON, Mass., September 22, 2021--Dicerna today announced new executive leadership appointments.

  • Business Wire

    Dicerna to Participate in 16th Annual Citi Biopharma Conference

    LEXINGTON, Mass., September 02, 2021--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16th Annual Citi Biopharma Conference on Sept. 9, 2021 at 7:55 a.m. ET.

  • TipRanks

    Is Dicerna Stock a Buy Right Now? This Is What You Need to Know

    The stock market’s behavior might appear baffling at times, but when you see shares of a biotech sinking, the reason is almost always one of two ready-made options: regulatory rejection or disappointing clinical trial results. For disappointed investors of Dicerna Pharmaceuticals (DRNA), the latter case sent the stock tumbling by 28% in a single session last week. Specifically, the downturn came about after the company released data from the phase 2 trial evaluating nedosiran as a treatment for